Top

Published in:

06-07-2023 | Rituximab | Review Article

Waldenström macroglobulinemia: a review of pathogenesis, current treatment, and future prospects

Authors: Bushra Ghafoor, Shameera Shaik Masthan, Maha Hameed, Hafiza Huda Akhtar, Azeem Khalid, Sana Ghafoor, Hassan min Allah, Mohammad Mohsin Arshad, Iman Iqbal, Ahmad Iftikhar, Muhammad Husnain, Faiz Anwer

Published in: Annals of Hematology | Issue 6/2024

Abstract

Waldenström macroglobulinemia (WM) is a chronic B-cell lymphoproliferative disorder characterized by lymphoplasmacytic cell overgrowth in the bone marrow and increased secretion of IgM immunoglobulins into the serum. Patients with WM have a variety of clinical outcomes, including long-term survival but inevitable recurrence. Recent advances in disease knowledge, including molecular and genetic principles with the discovery of MYD88 and CXCR4 mutations, have rapidly increased patient-tolerable treatment options. WM patients may benefit from chemotherapy regimens that include rituximab-based regimens, alkylating drugs, proteasome inhibitors, monoclonal antibodies, and drugs targeting Bruton tyrosine kinase inhibitors. In light of these advancements, patients can now receive treatment customized to their specific clinical characteristics, focusing on enhancing the depth and durability of their response while limiting the adverse effects. Despite the rapidly developing therapeutic armament against WM, a lack of high-quality evidence from extensive phase 3 trials remains a significant challenge in the research. We believe clinical outcomes will keep improving when new medicines are introduced while preserving efficacy and minimizing toxicity.

Wang H, Chen Y, Li F et al (2012) Temporal and geographic variations of Waldenstrom macroglobulinemia incidence: a large population-based study. Cancer 118(15):3793–3800. https://doi.org/10.1002/cncr.26627CrossRefPubMed

Kyle RA, Larson DR, McPhail ED et al (2018) Fifty-year incidence of Waldenström macroglobulinemia in Olmsted County, Minnesota, from 1961 through 2010: a population-based study with complete case capture and hematopathologic review. Mayo Clin Proc 93(6):739–746. https://doi.org/10.1016/j.mayocp.2018.02.011CrossRefPubMed

Juárez-Salcedo LM, Castillo JJ (2019) Lymphoplasmacytic lymphoma and marginal zone lymphoma. Hematol Oncol Clin North Am 33(4):639–656. https://doi.org/10.1016/j.hoc.2019.03.004CrossRefPubMed

Sekhar J, Sanfilippo K, Zhang Q, Trinkaus K, Vij R, Morgensztern D (2012) Waldenström macroglobulinemia: a surveillance, epidemiology, and end results database review from 1988 to 2005. Leuk Lymphoma 53(8):1625–1626. https://doi.org/10.3109/10428194.2012.656103CrossRefPubMed

Viera S, Ludek P, Zdeněk A et al (2018) Monoclonal gammopathy of undetermined significance (MGUS) monoclonal gammopathy of undetermined significance (MGUS). Klin Onkol 31(4):270–276. https://doi.org/10.14735/amko2018270CrossRefPubMed

Remstein ED, Hanson CA, Kyle RA, Hodnefield JM, Kurtin PJ (2003) Despite apparent morphologic and immunophenotypic heterogeneity, Waldenstrom’s macroglobulinemia is consistently composed of cells along a morphologic continuum of small lymphocytes, plasmacytoid lymphocytes, and plasma cells. Semin Oncol 30(2):182–186. https://doi.org/10.1053/sonc.2003.50073CrossRefPubMed

Ravi G, Kapoor P (2022) Current approach to Waldenström macroglobulinemia. Cancer Treat Res Commun 31:100527. https://doi.org/10.1016/j.ctarc.2022.100527CrossRefPubMed

Treon SP, Xu L, Guerrera ML et al (2020) Genomic landscape of Waldenström macroglobulinemia and its impact on treatment strategies. J Clin Oncol 38(11):1198–1208. https://doi.org/10.1200/JCO.19.02314CrossRefPubMedPubMedCentral

Treon SP, Xu L, Yang G et al (2012) MYD88 L265P somatic mutation in Waldenström’s macroglobulinemia. N Engl J Med 367(9):826–833. https://doi.org/10.1056/NEJMoa1200710CrossRefPubMed

10.

Ngo VN, Young RM, Schmitz R et al (2011) Oncogenically active MYD88 mutations in human lymphoma. Nature 470(7332):115–119. https://doi.org/10.1038/nature09671CrossRefPubMed

11.

Hunter ZR, Yang G, Xu L, Liu X, Castillo JJ, Treon SP (2017) Genomics, signaling, and treatment of Waldenström macroglobulinemia. J Clin Oncol 35(9):994–1001. https://doi.org/10.1200/JCO.2016.71.0814CrossRefPubMed

12.

Chapman MA, Lawrence MS, Keats JJ et al (2011) Initial genome sequencing and analysis of multiple myeloma. Nature 471(7339):467–472. https://doi.org/10.1038/nature09837CrossRefPubMedPubMedCentral

13.

Poulain S, Roumier C, Decambron A et al (2013) MYD88 L265P mutation in Waldenstrom macroglobulinemia. Blood 121(22):4504–4511. https://doi.org/10.1182/blood-2012-06-436329CrossRefPubMed

14.

Caruz A, Samsom M, Alonso JM, Alcami J, Baleux F, Virelizier JL, Parmentier M, Arenzana-Seisdedos F (1998) Genomic organization and promoter characterization of human CXCR4 gene. FEBS Lett 426(2):271–278. https://doi.org/10.1016/s0014-5793(98)00359-7CrossRefPubMed

15.

Kristinsson SY, Landgren O (2011) What causes Waldenström’s macroglobulinemia: genetic or immune-related factors, or a combination? Clin Lymphoma Myeloma Leuk 11(1):85–87. https://doi.org/10.3816/CLML.2011.n.015CrossRefPubMedPubMedCentral

16.

Treon SP, Meid K, Gustine J et al (2021) Long-term follow-up of ibrutinib monotherapy in symptomatic, previously treated patients with Waldenström macroglobulinemia. J Clin Oncol 39(6):565–575. https://doi.org/10.1200/JCO.20.00555CrossRefPubMed

17.

Castillo JJ, Ghobrial IM, Treon SP (2015) Biology, Prognosis, and therapy of Waldenström macroglobulinemia. In: Evens AM, Blum KA (eds) Non-Hodgkin Lymphoma. Vol 165. Cancer Treatment and Research. Springer International Publishing, pp 177–195. https://doi.org/10.1007/978-3-319-13150-4_7CrossRef

18.

Owen RG, Treon SP, Al-Katib A et al (2003) Clinicopathological definition of Waldenstrom’s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom’s Macroglobulinemia. Semin Oncol 30(2):110–115. https://doi.org/10.1053/sonc.2003.50082CrossRefPubMed

19.

Blanco P, Viallard JF, Rivel J, Leng B, Pellegrin JL (2000) Unusual manifestations of type II cryoglobulinaemia associated with Waldenström’s macroglobulinaemia. J Clin Pathol 53(11):882–884. https://doi.org/10.1136/jcp.53.11.882CrossRefPubMedPubMedCentral

20.

Nobile-Orazio E, Marmiroli P, Baldini L et al (1987) Peripheral neuropathy in macroglobulinemia: incidence and antigen-specificity of M proteins. Neurology 37(9):1506–1514. https://doi.org/10.1212/wnl.37.9.1506CrossRefPubMed

21.

Pratt G, El-Sharkawi D, Kothari J et al (2022) Diagnosis and management of Waldenström macroglobulinaemia-a British Society for Haematology guideline. Br J Haematol 197(2):171–187. https://doi.org/10.1111/bjh.18036CrossRefPubMed

22.

Gertz MA (2023) Waldenström macroglobulinemia: 2023 update on diagnosis, risk stratification, and management. Am J Hematol 98(2):348–358. https://doi.org/10.1002/ajh.26796CrossRefPubMedPubMedCentral

23.

Alcoceba M, García-Álvarez M, Medina A et al (2022) MYD88 mutations: transforming the landscape of IgM monoclonal gammopathies. Int J Mol Sci 23(10):5570. https://doi.org/10.3390/ijms23105570CrossRefPubMedPubMedCentral

24.

Kastritis E, Morel P, Duhamel A et al (2019) A revised international prognostic score system for Waldenström’s macroglobulinemia. Leukemia 33(11):2654–2661. https://doi.org/10.1038/s41375-019-0431-yCrossRefPubMed

25.

Kyle RA, Benson JT, Larson DR et al (2012) Progression in smoldering Waldenstrom macroglobulinemia: long-term results. Blood 119(19):4462–4466. https://doi.org/10.1182/blood-2011-10-384768CrossRefPubMedPubMedCentral

26.

Kyle RA, Treon SP, Alexanian R et al (2003) Prognostic markers and criteria to initiate therapy in Waldenstrom’s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom’s Macroglobulinemia. Semin Oncol 30(2):116–120. https://doi.org/10.1053/sonc.2003.50038CrossRefPubMed

27.

Buske C, Sadullah S, Kastritis E et al (2018) Treatment and outcome patterns in European patients with Waldenström’s macroglobulinaemia: a large, observational, retrospective chart review. Lancet Haematol 5(7):e299–e309. https://doi.org/10.1016/S2352-3026(18)30087-5CrossRefPubMed

28.

Perez Rogers A, Estes M (2022) Hyperviscosity syndrome. In: StatPearls. StatPearls Publishing http://www.ncbi.nlm.nih.gov/books/NBK518963/ Accessed December 10, 2022

29.

Treon SP (2015) How I treat Waldenström macroglobulinemia. Blood 126(6):721–732. https://doi.org/10.1182/blood-2015-01-553974CrossRefPubMed

30.

Dimopoulos MA, Zervas C, Zomas A et al (2002) Treatment of Waldenström’s macroglobulinemia with rituximab. J Clin Oncol 20(9):2327–2333. https://doi.org/10.1200/JCO.2002.09.039CrossRefPubMed

31.

Treon SP, Emmanouilides C, Kimby E et al (2005) Extended rituximab therapy in Waldenström’s macroglobulinemia. Ann Oncol 16(1):132–138. https://doi.org/10.1093/annonc/mdi022CrossRefPubMed

32.

Gertz MA, Rue M, Blood E, Kaminer LS, Vesole DH, Greipp PR (2004) Multicenter phase 2 trial of rituximab for Waldenström macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98). Leuk Lymphoma 45(10):2047–2055. https://doi.org/10.1080/10428190410001714043CrossRefPubMed

33.

Dimopoulos MA, Zervas C, Zomas A et al (2002) Extended rituximab therapy for previously untreated patients with Waldenström’s macroglobulinemia. Clin Lymphoma 3(3):163–166. https://doi.org/10.3816/clm.2002.n.022CrossRefPubMed

34.

Ghobrial IM, Fonseca R, Greipp PR et al (2004) Initial immunoglobulin M ‘flare’ after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group Study. Cancer 101(11):2593–2598. https://doi.org/10.1002/cncr.20658CrossRefPubMed

35.

Furman RR, Eradat H, Switzky JC et al (2010) A phase II trial of ofatumumab in subjects with Waldenstrom’s macroglobulinemia. Blood 118(21):3701. https://doi.org/10.1182/blood.V118.21.3701.3701CrossRef

36.

Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC et al (2007) Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. J Clin Oncol 25(22):3344–3349. https://doi.org/10.1200/JCO.2007.10.9926CrossRefPubMed

37.

Treon SP, Hanzis C, Tripsas C et al (2011) Bendamustine therapy in patients with relapsed or refractory Waldenström’s macroglobulinemia. Clin Lymphoma Myeloma Leuk 11(1):133–135. https://doi.org/10.3816/CLML.2011.n.030CrossRefPubMed

38.

Paludo J, Abeykoon JP, Shreders A et al (2018) Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia. Ann Hematol 97(8):1417–1425. https://doi.org/10.1007/s00277-018-3311-zCrossRefPubMed

39.

Tedeschi A, Picardi P, Ferrero S et al (2015) Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemia. Leuk Lymphoma 56(9):2637–2642. https://doi.org/10.3109/10428194.2015.1012714CrossRefPubMed

40.

Ioakimidis L, Patterson CJ, Hunter ZR et al (2009) Comparative outcomes following CP-R, CVP-R, and CHOP-R in Waldenström’s macroglobulinemia. Clin Lymphoma Myeloma 9(1):62–66. https://doi.org/10.3816/CLM.2009.n.016CrossRefPubMed

41.

Laribi K, Poulain S, Willems L et al (2019) Bendamustine plus rituximab in newly-diagnosed Waldenström macroglobulinaemia patients. A study on behalf of the French Innovative Leukaemia Organization (FILO). Br J Haematol 186(1):146–149. https://doi.org/10.1111/bjh.15718CrossRefPubMed

42.

Buske C, Dimopoulos MA, Grunenberg A, Kastritis E, Tomowiak C, Mahé B, Troussard X, Hajek R, Viardot A, Tournilhac O, Aurran T (2023) Bortezomib-dexamethasone, rituximab, and cyclophosphamide as first-line treatment for Waldenström’s macroglobulinemia: a prospectively randomized trial of the European consortium for Waldenström’s macroglobulinemia. J Clin Oncol 41(14):2607–2616. https://doi.org/10.1200/JCO.22.01805CrossRefPubMed

43.

Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grünhagen U, Losem C, Kofahl-Krause D, Heil G, Welslau M, Balser C, Kaiser U (2013) Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 381(9873):1203–1210. https://doi.org/10.1016/S0140-6736(12)61763-2 Erratum in: Lancet. 2013 Apr 6;381(9873):1184CrossRefPubMed

44.

Souchet-Compain L, Nguyen S, Choquet S, Leblond V (2013) Fludarabine in Waldenstrom’s macroglobulinemia. Expert Rev Hematol 6(3):229–237. https://doi.org/10.1586/ehm.13.17CrossRefPubMed

45.

Laszlo D, Andreola G, Rigacci L et al (2010) Rituximab and subcutaneous 2-chloro-2′-deoxyadenosine combination treatment for patients with Waldenström macroglobulinemia: clinical and biologic results of a phase ii multicenter study. J Clin Oncol 28(13):2233–2238. https://doi.org/10.1200/JCO.2009.23.6315CrossRefPubMed

46.

Tedeschi A, Benevolo G, Varettoni M et al (2012) Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease. Cancer 118(2):434–443. https://doi.org/10.1002/cncr.26303CrossRefPubMed

47.

Treon SP, Branagan AR, Ioakimidis L et al (2009) Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia. Blood 113(16):3673–3678. https://doi.org/10.1182/blood-2008-09-177329CrossRefPubMedPubMedCentral

48.

Leleu X, Soumerai J, Roccaro A et al (2009) Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs. J Clin Oncol 27(2):250–255. https://doi.org/10.1200/JCO.2007.15.1530CrossRefPubMed

49.

Tournilhac O (2004) Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia. Blood 103(1):363–365. https://doi.org/10.1182/blood-2003-05-1449CrossRefPubMed

50.

Treon SP (2013) Proteasome inhibitors in Waldenström macroglobulinemia. Blood 122(19):3243–3244. https://doi.org/10.1182/blood-2013-09-526335CrossRefPubMed

51.

Dimopoulos MA, Terpos E, Kastritis E (2013) Proteasome inhibitor therapy for Waldenström’s macroglobulinemia. Clin Lymphoma Myeloma Leuk 13(2):235–237. https://doi.org/10.1016/j.clml.2013.02.014CrossRefPubMed

52.

Treon SP, Ioakimidis L, Soumerai JD et al (2009) Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. J Clin Oncol 27(23):3830–3835. https://doi.org/10.1200/JCO.2008.20.4677CrossRefPubMedPubMedCentral

53.

Ghobrial IM, Hong F, Padmanabhan S et al (2010) Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenström macroglobulinemia. J Clin Oncol 28(8):1422–1428. https://doi.org/10.1200/JCO.2009.25.3237CrossRefPubMedPubMedCentral

54.

Chen CI, Kouroukis CT, White D et al (2007) Bortezomib is active in patients with untreated or relapsed Waldenström’s macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25(12):1570–1575. https://doi.org/10.1200/JCO.2006.07.8659CrossRefPubMed

55.

Castillo JJ, Meid K, Flynn CA, Chen J, Demos MG, Guerrera ML, Kofides A, Liu X, Munshi M, Tsakmaklis N, Patterson CJ (2020) Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenström macroglobulinemia: long-term follow-up. Blood Adv 4(16):3952–3959CrossRefPubMedPubMedCentral

56.

Treon SP, Tripsas CK, Meid K et al (2014) Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström’s macroglobulinemia. Blood 124(4):503–510. https://doi.org/10.1182/blood-2014-03-566273CrossRefPubMed

57.

Ilhan O, Cengiz Seval G, Avcu F et al (2022) PB2074: Ibrutinib as a promising treatment for Waldenström macroglobulinemia. HemaSphere 6:1945–1946. https://doi.org/10.1097/01.HS9.0000851128.52895.ecCrossRefPubMedCentral

58.

Castillo JJ, Gustine JN, Meid K et al (2020) Response and survival outcomes to ibrutinib monotherapy for patients with Waldenström macroglobulinemia on and off clinical trials. HemaSphere 4(3):e363. https://doi.org/10.1097/HS9.0000000000000363CrossRefPubMedPubMedCentral

59.

Buske C, Tedeschi A, Trotman J et al (2022) Ibrutinib plus rituximab versus placebo plus rituximab for Waldenström’s macroglobulinemia: final analysis from the randomized phase III innovate study. J Clin Oncol 40(1):52–62. https://doi.org/10.1200/JCO.21.00838CrossRefPubMed

60.

Buske C, Hess G, Bahar N et al (2022) PB2081: treatment persistence and adherence to ibrutinib in patients with Waldenström macroglobulinemia: a German claims data analysis. HemaSphere 6:1952–1953. https://doi.org/10.1097/01.HS9.0000851156.61481.73CrossRefPubMedCentral

61.

Trotman J, Opat S, Gottlieb D et al (2020) Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up. Blood 136(18):2027–2037. https://doi.org/10.1182/blood.2020006449CrossRefPubMedPubMedCentral

62.

Sekiguchi N, Rai S, Munakata W et al (2020) A multicenter, open-label, phase II study of tirabrutinib (ONO/GS-4059) in patients with Waldenström’s macroglobulinemia. Cancer Sci 111(9):3327–3337. https://doi.org/10.1111/cas.14561CrossRefPubMedPubMedCentral

63.

An G, Zhou D, Cheng S et al (2021) A phase II trial of the Bruton tyrosine-kinase inhibitor zanubrutinib (BGB-3111) in patients with relapsed/refractory Waldenström macroglobulinemia. Clin Cancer Res 27(20):5492–5501. https://doi.org/10.1158/1078-0432.CCR-21-0539CrossRefPubMedPubMedCentral

64.

Tam CS, Opat S, D’Sa S et al (2020) A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study. Blood 136(18):2038–2050. https://doi.org/10.1182/blood.2020006844CrossRefPubMedPubMedCentral

65.

Dimopoulos M, Sanz RG, Lee HP et al (2020) Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial. Blood Adv 4(23):6009–6018. https://doi.org/10.1182/bloodadvances.2020003010CrossRefPubMedPubMedCentral

66.

Owen RG, McCarthy H, Rule S et al (2020) Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study. Lancet Haematol 7(2):e112–e121. https://doi.org/10.1016/S2352-3026(19)30210-8CrossRefPubMed

67.

Castillo JJ, Allan JN, Siddiqi T et al (2022) Venetoclax in previously treated Waldenström macroglobulinemia. J Clin Oncol 40(1):63–71. https://doi.org/10.1200/JCO.21.01194CrossRefPubMed

68.

Kaiser LM, Harms M, Sauter D et al (2021) Targeting of CXCR4 by the naturally occurring CXCR4 antagonist EPI-X4 in Waldenström’s macroglobulinemia. Cancers 13(4):826. https://doi.org/10.3390/cancers13040826CrossRefPubMedPubMedCentral

69.

Treon SP, Meid K, Hunter ZR et al (2021) Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemia. Blood 138(17):1535–1539. https://doi.org/10.1182/blood.2021012953CrossRefPubMedPubMedCentral

70.

Anagnostopoulos A, Hari PN, Pérez WS et al (2006) Autologous or allogeneic stem cell transplantation in patients with Waldenstrom’s macroglobulinemia. Biol Blood Marrow Transplant 12(8):845–854. https://doi.org/10.1016/j.bbmt.2006.04.010CrossRefPubMed

71.

Gilleece MH, Pearce R, Linch DC et al (2008) The outcome of haemopoietic stem cell transplantation in the treatment of lymphoplasmacytic lymphoma in the UK: a British Society Bone Marrow Transplantation study. Hematology 13(2):119–127. https://doi.org/10.1179/102453308X315915CrossRefPubMed

72.

Dhedin N, Tabrizi R, Bulabois PE et al (2007) Hematopoietic stem cell transplantation (HSCT) in Waldenström macroglobulinemia (Wm), Update of the French experience in 54 cases. Blood 110(11):3015–3015. https://doi.org/10.1182/blood.V110.11.3015.3015CrossRef

73.

Kyriakou C, Canals C, Sibon D et al (2010) High-dose therapy and autologous stem-cell transplantation in Waldenström macroglobulinemia: the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol 28(13):2227–2232. https://doi.org/10.1200/JCO.2009.24.4905CrossRefPubMed

Title: Waldenström macroglobulinemia: a review of pathogenesis, current treatment, and future prospects
Authors: Bushra Ghafoor
Shameera Shaik Masthan
Maha Hameed
Hafiza Huda Akhtar
Azeem Khalid
Sana Ghafoor
Hassan min Allah
Mohammad Mohsin Arshad
Iman Iqbal
Ahmad Iftikhar
Muhammad Husnain
Faiz Anwer
Publication date: 06-07-2023
Publisher: Springer Berlin Heidelberg
Keywords: Rituximab
Rituximab
Ibrutinib
Zanubrutinib
Alkylating Agent
Lymphoma
Published in: Annals of Hematology / Issue 6/2024
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-023-05345-9

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2024

Impact of genotype on multi-organ iron and complications in patients with non-transfusion-dependent β-thalassemia intermedia

Thiotepa-busulfan-fludarabine-based conditioning as a promising approach prior to allogeneic hematopoietic stem cell transplantation in patients with blastic plasmacytoid dendritic cell neoplasm

Inhibition of NRF2 signaling overcomes acquired resistance to arsenic trioxide in FLT3-mutated Acute Myeloid Leukemia

Low incidence of tumor lysis syndrome in elderly patients with chronic lymphocytic leukemia treated with venetoclax under real-world conditions: results from the prospective observational VeRVe study

Could it be VEXAS?

CRISPR-Cas9 system: a novel and promising era of genotherapy for beta-hemoglobinopathies, hematological malignancy, and hemophilia

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials